Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Dehydroborapetoside B

$1,120

  • Brand : BIOFRON

  • Catalogue Number : BN-B0509

  • Specification : 95%(HPLC)

  • CAS number : 1221178-16-0

  • Formula : C27H34O12

  • Molecular Weight : 550.55

  • PUBCHEM ID : 46211471

  • Volume : 5mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BN-B0509

Analysis Method

HPLC,NMR,MS

Specification

95%(HPLC)

Storage

2-8°C

Molecular Weight

550.55

Appearance

Powder

Botanical Source

Structure Type

Diterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC12CC(OC(=O)C1=CC(C3(C2CC(C=C3C(=O)OC)O)C)OC4C(C(C(C(O4)CO)O)O)O)C5=COC=C5

Synonyms

2H-Naphtho[2,1-c]pyran-7-carboxylic acid, 2-(3-furanyl)-6-(β-D-glucopyranosyloxy)-1,4,6,6a,9,10,10a,10b-octahydro-9-hydroxy-6a,10b-dimethyl-4-oxo-, methyl ester, (2S,6S,6aR,9R,10aS,10bS)-/Methyl (2S,6S,6aR,9R,10aS,10bS)-2-(3-furyl)-6-(β-D-glucopyranosyloxy)-9-hydroxy-6a,10b-dimethyl-4-oxo-1,4,6,6a,9,10,10a,10b-octahydro-2H-benzo[f]isochromene-7-carboxylate

IUPAC Name

methyl (2S,6S,6aR,9R,10aS,10bS)-2-(furan-3-yl)-9-hydroxy-6a,10b-dimethyl-4-oxo-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,6,9,10,10a-hexahydrobenzo[f]isochromene-7-carboxylate

Applications

Density

1.5±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

432.5±32.9 °C

Boiling Point

791.5±60.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C27H34O12/c1-26-9-16(12-4-5-36-11-12)37-24(34)14(26)8-19(39-25-22(32)21(31)20(30)17(10-28)38-25)27(2)15(23(33)35-3)6-13(29)7-18(26)27/h4-6,8,11,13,16-22,25,28-32H,7,9-10H2,1-3H3/t13-,16-,17+,18-,19-,20+,21-,22+,25-,26+,27-/m0/s1

InChl Key

CGKGCFDWGXCUDW-CGNVXPGMSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:1221178-16-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28101530

Abstract

Throughout childhood and adolescence, periods of heightened neuroplasticity are critical for the development of healthy brain function and behavior. Given the high prevalence of neurodevelopmental disorders, such as autism, identifying disruptors of developmental plasticity represents an essential step for developing strategies for prevention and intervention. Applying a novel computational approach that systematically assessed connections between 436 transcriptional signatures of disease and multiple signatures of neuroplasticity, we identified inflammation as a common pathological process central to a diverse set of diseases predicted to dysregulate plasticity signatures. We tested the hypothesis that inflammation disrupts developmental cortical plasticity in vivo using the mouse ocular dominance model of experience-dependent plasticity in primary visual cortex. We found that the administration of systemic lipopolysaccharide suppressed plasticity during juvenile critical period with accompanying transcriptional changes in a particular set of molecular regulators within primary visual cortex. These findings suggest that inflammation may have unrecognized adverse consequences on the postnatal developmental trajectory and indicate that treating inflammation may reduce the burden of neurodevelopmental disorders.

KEYWORDS

bioinformatics, critical period, inflammation, plasticity, transcriptome, visual cortex

Title

Integrative Analysis of Disease Signatures Shows Inflammation Disrupts Juvenile Experience-Dependent Cortical Plasticity

Author

Milo R. Smith,1,2,3,4,5,6,7,8 Poromendro Burman,1,3,4,5,8 Masato Sadahiro,1,3,4,5,6,8 Brian A. Kidd,2,7 Joel T. Dudley,corresponding author2,7 and Hirofumi Morishitacorresponding author1,3,4,5,8

Publish date

2016 Nov-Dec;